NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Net Debt Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual net debt in 2023 was -11.46 Million CAD , up 48.29% from previous year.
NervGen Pharma Corp.'s latest quarterly net debt in 2024 Q2 was -26.4 Million CAD , up 12.35% from previous quarter.
NervGen Pharma Corp. reported annual net debt of -22.16 Million CAD in 2022, down -30.95% from previous year.
NervGen Pharma Corp. reported annual net debt of -16.92 Million CAD in 2021, down -202.38% from previous year.
NervGen Pharma Corp. reported quarterly net debt of -26.4 Million CAD for 2024 Q2, up 12.35% from previous quarter.
NervGen Pharma Corp. reported quarterly net debt of -11.46 Million CAD for 2023 FY, up 48.29% from previous quarter.

Annual Net Debt Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Net Debt of NervGen Pharma Corp. (2023 - 2017)

Year	Net Debt	Net Debt Growth
2023	-11.46 Million CAD	48.29%
2022	-22.16 Million CAD	-30.95%
2021	-16.92 Million CAD	-202.38%
2020	-5.59 Million CAD	-36.34%
2019	-4.1 Million CAD	-65.95%
2018	-2.47 Million CAD	0.0%
2017	- CAD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-30.12 Million CAD	-162.85%
2024 Q2	-26.4 Million CAD	12.35%
2023 FY	-11.46 Million CAD	48.29%
2023 Q3	-14.56 Million CAD	8.05%
2023 Q1	-17.75 Million CAD	19.89%
2023 Q2	-15.84 Million CAD	10.8%
2023 Q4	-11.46 Million CAD	21.31%
2022 Q1	-12.82 Million CAD	24.22%
2022 FY	-22.16 Million CAD	-30.95%
2022 Q2	-11.32 Million CAD	11.72%
2022 Q4	-22.16 Million CAD	19.08%
2022 Q3	-27.39 Million CAD	-141.9%
2021 Q1	-4.98 Million CAD	10.93%
2021 FY	-16.92 Million CAD	-202.38%
2021 Q4	-16.92 Million CAD	-105.21%
2021 Q3	-8.24 Million CAD	-12.09%
2021 Q2	-7.35 Million CAD	-47.58%
2020 FY	-5.59 Million CAD	-36.34%
2020 Q2	-3.45 Million CAD	-37.57%
2020 Q4	-5.59 Million CAD	26.87%
2020 Q3	-7.65 Million CAD	-121.53%
2020 Q1	-2.51 Million CAD	38.82%
2019 Q1	-9.09 Million CAD	-267.73%
2019 FY	-4.1 Million CAD	-65.95%
2019 Q4	-4.1 Million CAD	34.54%
2019 Q3	-6.27 Million CAD	24.16%
2019 Q2	-8.27 Million CAD	9.11%
2018 FY	-2.47 Million CAD	0.0%
2018 Q4	-2.47 Million CAD	0.0%
2017 FY	- CAD	0.0%

Peer Net Debt Comparison of NervGen Pharma Corp.

Name	Net Debt	Net Debt Difference
Arch Biopartners Inc.	4.18 Million CAD	373.897%
Covalon Technologies Ltd.	-7.23 Million CAD	-58.491%
Hemostemix Inc.	4.16 Million CAD	375.135%
Universal Ibogaine Inc.	1.01 Million CAD	1233.062%
Kane Biotech Inc.	7.52 Million CAD	252.289%
MedMira Inc.	9.25 Million CAD	223.81%
Marvel Biosciences Corp.	443.37 Thousand CAD	2685.233%
XORTX Therapeutics Inc.	-4.53 Million CAD	-152.981%